Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 plus furmonertinib in EGFR-mutated advanced or metastatic NSCLC (Phase II)
CTR20244130Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lumipodlin and furmonertinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Abbisko Therapeutics. Primary endpoints: Dose-limiting toxicity (DLT) incidence in Cycle 1, Adverse events and 1 more. Started Dec 2024; status: active.
02
Drugs
lumipodlinfurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244130.